Biocon Pharma receives USFDA approval for daptomycin
The approval further adds to Biocon’s portfolio of complex drug products
The approval further adds to Biocon’s portfolio of complex drug products
The company will take all necessary steps to work with USFDA towards earliest remediation of the above facility
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
Subscribe To Our Newsletter & Stay Updated